Fulgent Genetics raises FY25 EPS view to 30c from (35c), consensus (35c)

Raises FY25 revenue view to $325M from $320M, consensus $320.12M. The company said, “Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the Company’s ongoing stock repurchase program, or other expenditures outside the ordinary course of business, including M&A. This number further assumes receipt of approximately $106 million in tax refunds prior to December 31, 2025, which may be delayed as a result of the current government shutdown.”